Latest news

• Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

  Roche has announced positive results from a late-stage study of its ALK inhibitor, Alecensa (alectinib), in early-stage lung cancer. ... Alecensa is already approved in over 100 countries as a first-line treatment for ALK-positive, metastatic NSCLC.

• Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

  Lorbrena is also an important follow-up to Pfizer’s older ALK inhibitor Xalkori, which has come under pressure as it faces increasing competition from Roche’s Alecensa (alectinib) and Novartis’

• Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

  Sales of Xalkori have come under pressure recently as it faces increasing pressure from Roche’s Alecensa (alectinib) and Novartis’ Zykadia (ceritinib), with both therapies having previously bested Pfizer’s ... Although Lorbrena will face extreme

• Roche reports continued growth in Q3, despite biosimilar competition

  In Europe, sales were down 1% thanks to the competition from biosimilars for Herception and Rituxan, but there was growth reported in the uptake of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra.

• Pfizer’s Talzenna cleared for breast cancer in Europe

  Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).